Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
复制标题
先前感染状态，定量SARS-COV-2抗尖峰反应对辉瑞-biontech和牛津 - 震中疫苗的反应。
DOI：
10.1016/j.cmi.2021.05.041
复制
发表时间：
2021-10
期刊：
影响因子：
--
通讯作者：
Jeffery K
中科院分区：
文献类型：
--
作者：
Eyre DW;Lumley SF;Wei J;Cox S;James T;Justice A;Jesuthasan G;O'Donnell D;Howarth A;Hatch SB;Marsden BD;Jones EY;Stuart DI;Ebner D;Hoosdally S;Crook DW;Peto TEA;Walker TM;Stoesser NE;Matthews PC;Pouwels KB;Walker AS;Jeffery K
我们研究了医务人员（HCW）接种一剂或两剂辉瑞-BioNTech或牛津-阿斯利康疫苗后严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗刺突IgG应答的决定因素。参加常规SARS-CoV-2 PCR和抗体检测的医务人员在第一次和第二次接种前以及接种后4周（如果接受12周给药间隔）接受血清学检测。使用Abbott SARS-CoV-2 IgG II Quant检测试剂盒（检测阈值：≥50 Au/mL）测定定量接种后抗刺突抗体应答。我们使用多变量逻辑回归来确定血清阳性的预测因子，并使用广义相加模型来跟踪抗体应答随时间的变化。3570/3610名HCW（98.9%）在第一次接种后>14天和第二次接种前为血清阳性：2706/2720（99.5%）在Pfizer-BioNTech疫苗后为血清阳性，864/890（97.1%）在Oxford-AstraZeneca疫苗后为血清阳性。先前感染和年轻的HCW更可能在第一次接种后检测血清阳性，没有证据表明性别或种族差异。第二次接种后>14天检测的所有470名HCW均为血清阳性。先前感染后的定量抗体应答更高：首次Pfizer-BioNTech后中位数（IQR）>21天14 604（7644-22 291）Au/mL，而没有先前感染时为1028（564-1985）Au/mL（p < 0.001）。牛津-阿斯利康疫苗接种者在首次接种后的读数低于辉瑞-BioNTech接种者，既往感染和未感染分别为10 095（5354-17 096）和435（203-962）Au/mL（与辉瑞-BioNTech相比均p < 0.001）。在第二次辉瑞疫苗接种后>21天，先前未感染的患者的抗体应答为10 058（6408-15 582）Au/mL，与先前感染后接种一剂疫苗后的抗体应答相似。SARS-CoV-2疫苗接种导致几乎所有成年HCW中可检测到抗刺突抗体。反应的差异是否影响疫苗的效力需要进一步研究。
We investigated determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike IgG responses in healthcare workers (HCWs) following one or two doses of Pfizer–BioNTech or Oxford–AstraZeneca vaccines. HCWs participating in regular SARS-CoV-2 PCR and antibody testing were invited for serological testing prior to first and second vaccination, and 4 weeks post-vaccination if receiving a 12-week dosing interval. Quantitative post-vaccination anti-spike antibody responses were measured using the Abbott SARS-CoV-2 IgG II Quant assay (detection threshold: ≥50 AU/mL). We used multivariable logistic regression to identify predictors of seropositivity and generalized additive models to track antibody responses over time. 3570/3610 HCWs (98.9%) were seropositive >14 days post first vaccination and prior to second vaccination: 2706/2720 (99.5%) were seropositive after the Pfizer–BioNTech and 864/890 (97.1%) following the Oxford–AstraZeneca vaccines. Previously infected and younger HCWs were more likely to test seropositive post first vaccination, with no evidence of differences by sex or ethnicity. All 470 HCWs tested >14 days after the second vaccination were seropositive. Quantitative antibody responses were higher after previous infection: median (IQR) >21 days post first Pfizer–BioNTech 14 604 (7644–22 291) AU/mL versus 1028 (564–1985) AU/mL without prior infection (p < 0.001). Oxford–AstraZeneca vaccine recipients had lower readings post first dose than Pfizer–BioNTech recipients, with and without previous infection, 10 095 (5354–17 096) and 435 (203–962) AU/mL respectively (both p < 0.001 versus Pfizer–BioNTech). Antibody responses >21 days post second Pfizer vaccination in those not previously infected, 10 058 (6408–15 582) AU/mL, were similar to those after prior infection followed by one vaccine dose. SARS-CoV-2 vaccination leads to detectable anti-spike antibodies in nearly all adult HCWs. Whether differences in response impact vaccine efficacy needs further study.
登录
查看更多内容
DOI：
10.1016/s0140-6736(21)00432-3
发表时间：
2021-03-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Costa Clemens SA;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Clutterbuck EA;Collins AM;Cutland CL;Darton TC;Dheda K;Dold C;Duncan CJA;Emary KRW;Ewer KJ;Flaxman A;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Galiza E;Goodman AL;Green CM;Green CA;Greenland M;Hill C;Hill HC;Hirsch I;Izu A;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Libri V;Lillie PJ;Marchevsky NG;Marshall RP;Mendes AVA;Milan EP;Minassian AM;McGregor A;Mujadidi YF;Nana A;Padayachee SD;Phillips DJ;Pittella A;Plested E;Pollock KM;Ramasamy MN;Ritchie AJ;Robinson H;Schwarzbold AV;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;White T;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1056/nejmoa2034545
发表时间：
2021-02-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Lumley SF;O'Donnell D;Stoesser NE;Matthews PC;Howarth A;Hatch SB;Marsden BD;Cox S;James T;Warren F;Peck LJ;Ritter TG;de Toledo Z;Warren L;Axten D;Cornall RJ;Jones EY;Stuart DI;Screaton G;Ebner D;Hoosdally S;Chand M;Crook DW;O'Donnell AM;Conlon CP;Pouwels KB;Walker AS;Peto TEA;Hopkins S;Walker TM;Jeffery K;Eyre DW;Oxford University Hospitals Staff Testing Group
通讯作者：
Oxford University Hospitals Staff Testing Group
DOI：
10.1016/s1473-3099(20)30634-4
发表时间：
2020-12
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
National SARS-CoV-2 Serology Assay Evaluation Group
通讯作者：
National SARS-CoV-2 Serology Assay Evaluation Group
影响因子：
16.6
作者：
GeurtsvanKessel, Corine H.;Okba, Nisreen M. A.;Koopmans, Marion
通讯作者：
Koopmans, Marion
DOI：
10.1093/cid/ciab004
发表时间：
2021-08-02
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Lumley SF;Wei J;O'Donnell D;Stoesser NE;Matthews PC;Howarth A;Hatch SB;Marsden BD;Cox S;James T;Peck LJ;Ritter TG;de Toledo Z;Cornall RJ;Jones EY;Stuart DI;Screaton G;Ebner D;Hoosdally S;Crook DW;Conlon CP;Pouwels KB;Walker AS;Peto TEA;Walker TM;Jeffery K;Eyre DW;Oxford University Hospitals Staff Testing Group
通讯作者：
Oxford University Hospitals Staff Testing Group